Leukoregulin Enhancement of Tumor Inhibitory Drug Uptake
Leukoregulin is a 32 kDa glycoprotein cytokine secreted by lymphocytes and monocytes which possesses unique regulatory activities for tumor cells and for cells undergoing transformation to the neoplastic state [1, 2]. These anticancer actions include (a) prevention of chemical carcinogen and radiation-induced transformation, (b) inhibition of neoplastic cell proliferation, (c) increased plasma membrane permeability associated with enhancement of target cell sensitivity to natural killer cell cytotoxicity, and (d) lysis of neoplastic cells.
KeywordsPermeability High Performance Liquid Chromatography Lymphoma Adenosine Electrophoresis
Unable to display preview. Download preview PDF.
- 2.Evans CH (1988) Mechanisms of leukoregulin anti-cancer action. In:Ransom JH, Ortaldo J (eds) Leukolysins and cancer:biological and chemical Aspects Humana, Clifton, pp 198–216Google Scholar
- 3.Evans CH, Ransom JH (1984) The anti-cancer action of lymphotoxin. In:Goldstein AL (ed) Thymic hormones and lymphokines Plenum, New York, pp 357–364Google Scholar
- 4.Cleveland L, Ransom JH, Evans CH (1984). Leukoregulin, a new anticancer lymphokine distinct from lymphotoxin and interferon. Fed Proc 43:1931Google Scholar
- 5.Evans CH (1984) Rapid flow cytometric quantitation of leukoregulin, the dominant direct acting anti-tumor lymphokine in lymphotoxin preparations. Fed Proc 43:1970Google Scholar
- 12.Trinchieri G, Santoli D (1978) Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 147:1314–1317PubMedCrossRefGoogle Scholar